Current Report · Items 5.03 · 8-K

Curis, Inc.

CRISNASDAQEQUITYCurrent

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Filed Jul 1, 2026Accepted Jul 1, 2026, 8:02 AM EDTCIK 1108205Accession 0001108205-26-000074

Company context

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).

Current securities

CRISNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.03

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.03Item 5.03 - Amendments to Articles/Bylaws

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously disclosed, Curis, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) on June 25, 2026, at which the Company’s stockholders approved the adoption and approval of amendments to the Company’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding shares of common stock, by a ratio ranging from any whole number between 1-for-5 and 1-for-25, as determined by the Company’s Board of Directors (the “Board”) in its discretion, subject to the Board’s authority to abandon any or all such amendments (the “Reverse Stock Split Certificate of Amendment”). On June 25, 2026, following stockholder approval of the Reverse Stock Split Certificate of Amendment at the Special Meeting, the Board approved a 1-for-20 reverse stock split of Company’s issued and outstanding shares of common stock.